Kalyanee Viraswami-Appanna
Bristol-Myers Squibb (United States) · 14 works · 863 citations · h-index 9
Top works
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
- Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
- Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
- Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
- Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study
- Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial
- Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
- Accelerating drug development at Bristol Myers Squibb through innovation
- Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development
- Abstract #860: Glycemic Efficacy and Safety of Muraglitazar, a Novel Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, in Patients with Type 2 Diabetes: Results of a Double-Blind, Randomized, Parallel-Group, Dose-Comparison Study
- Abstract #866: Glycemic Efficacy and Tolerability of Muraglitazar, a Novel Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, in Drug-Naïve Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation
- Using Bayesian proof-of-concept criteria to design randomized phase II oncology trials stratified by biomarker status.